RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
109 hedge funds and large institutions have $847M invested in RAPT Therapeutics in 2021 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 35 increasing their positions, 23 reducing their positions, and 10 closing their positions.
372% more capital inflows, than outflows
Capital inflows: $164M | Capital outflows: $34.8M
300% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 10
52% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 23
40% more funds holding
Funds holding: 78 → 109 (+31)
33% more funds holding in top 10
Funds holding in top 10: 9 → 12 (+3)
5.89% more ownership
Funds ownership: 84.85% → 90.74% (+5.9%)
2% less call options, than puts
Call options by funds: $53.3M | Put options by funds: $54.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23.7M |
| 2 |
GTC
Ghost Tree Capital
New York
|
+$13.3M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$12.8M |
| 4 |
Caption Management
Oklahoma City,
Oklahoma
|
+$9.8M |
| 5 |
VR Adviser
New York
|
+$9.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPCB XV Associates
Menlo Park,
California
|
-$15.2M |
| 2 |
Regents of the University of California
Oakland,
California
|
-$5.08M |
| 3 |
Acuta Capital Partners
Redwood City,
California
|
-$4.45M |
| 4 |
Millennium Management
New York
|
-$1.84M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$1.55M |
RAPT Hedge Fund Activity: Q2 2021 in Review
109 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q2 2021, worth a combined $847M — up 81% from $468M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new RAPT positions and 10 closed out — a net gain of 30 holders — while 35 added to existing stakes and 23 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $23.7M. The largest seller was KPCB XV Associates, cutting an estimated $15.2M.
- 109 institutional investors held RAPT Therapeutics (RAPT) as of Q2 2021, up from 78 in Q1 2021.
- Funds reported $847M of RAPT Therapeutics stock for Q2 2021, up 81% quarter-over-quarter.
- 40 funds opened new RAPT Therapeutics positions in Q2 2021 and 10 closed out, a net change of +30 holders.
- The largest RAPT Therapeutics buyer in Q2 2021 was T. Rowe Price Associates, an estimated $23.7M added.
- The largest RAPT Therapeutics seller in Q2 2021 was KPCB XV Associates, an estimated $15.2M sold.
Based on aggregated 13F filings for Q2 2021.